Development and Validation of a Predictive Model for Glycemic Response to Dorzagliatin in Type 2 Diabetes: A Retrospective Real-World Study
X-Disciplinarity · 2025
DOI: 10.63174/xdi.dbxs5758 ↗Kurz gefasst
Fachartikel in der Zeitschrift X-Disciplinarity, 2025. Verfasst von Yue Liu und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Patient response to dorzagliatin, a novel glucokinase activator for type 2 diabetes mellitus (T2DM), exhibits significant heterogeneity in clinical practice, posing a challenge for precision medicine. This study aimed to develop and validate a predictive model for identifying optimal responders prior to treatment initiation. We conducted a retrospective cohort study involving 300 T2DM patients hospitalized between April 2024 and April 2025. Patients were categorized into a responder group (n=146, fasting/postprandial glucose reduction >0.5 mmol/L) and a non-responder group (n=154, reduction
Zitieren
APA
Liu, Y., Liu, J., Yan, Z., Chen, Y., & Han, L. (2025). Development and Validation of a Predictive Model for Glycemic Response to Dorzagliatin in Type 2 Diabetes: A Retrospective Real-World Study. X-Disciplinarity. https://doi.org/10.63174/xdi.dbxs5758
Vancouver
Liu Y, Liu J, Yan Z, Chen Y, Han L. Development and Validation of a Predictive Model for Glycemic Response to Dorzagliatin in Type 2 Diabetes: A Retrospective Real-World Study. X-Disciplinarity. 2025. doi:10.63174/xdi.dbxs5758
BibTeX
@article{Liu2025,
author = {Liu, Yue and Liu, Jia and Yan, Zhongqing and Chen, Ying and Han, Liping},
title = {Development and Validation of a Predictive Model for Glycemic Response to Dorzagliatin in Type 2 Diabetes: A Retrospective Real-World Study},
journal = {X-Disciplinarity},
year = {2025},
doi = {10.63174/xdi.dbxs5758}
}
EUVIMED